CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, cilt.25, sa.3, ss.463-469, 2016 (SCI-Expanded)
Background: A previous analysis of the placebo arm of the Prostate Cancer Prevention Trial (PCPT) reported 82% overall prevalence of intraprostatic inflammation and identified a link between inflammation and higher-grade prostate cancer and serum PSA. Here, we studied these associations in the PCPT finasteride arm.